Real-World Safety, Tolerability and Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Final Report of Post-marketing Surveillance in Japan
Advances in Therapy · 2025-02 · 42 (2) · 1075-1093
DOI: 10.1007/s12325-024-03079-2 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Advances in Therapy, online erschienen am 23.12.2024. Verfasst von Yoshikazu Inoue und 9 weiteren Autor:innen. Beteiligte Einrichtung: Osaka Anti-Tuberculosis Association, Osaka Fukujuji Hospital, Osaka, Japan. giichiyi@me.com. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis, Indoles, Protein Kinase Inhibitors. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Nippon Boehringer Ingelheim Co., Ltd..
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Osaka Anti-Tuberculosis Association, Osaka Fukujuji Hospital, Osaka, Japan. giichiyi@me.com.
- Clinical Research Center, NHO Kinki Chuo Chest Medical Center, 1180 Nagasone-Cho, Kita-Ku, Sakai, Osaka, 591-8555, Japan. giichiyi@me.com.
- Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Kanagawa, Japan.
- Mihara General Hospital, Saitama, Japan.
- Nippon Medical School, Tokyo, Japan.
- Department of Respiratory Medicine and Allergy, Tosei General Hospital, Aichi, Japan.
ORCID-Profile: Yoshikazu Inoue, Arata Azuma, Yasuhiro Kondoh, Toshihiro Nukiwa
Förderung
- Nippon Boehringer Ingelheim Co., Ltd.
Zitieren
APA
Inoue, Y., Ogura, T., Azuma, A., Kondoh, Y., Homma, S., Muraishi, K., Ikeda, R., Ochiai, K., Sugiyama, Y., & Nukiwa, T. (2025). Real-World Safety, Tolerability and Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Final Report of Post-marketing Surveillance in Japan. Advances in Therapy, 42(2), 1075-1093. https://doi.org/10.1007/s12325-024-03079-2
Vancouver
Inoue Y, Ogura T, Azuma A, Kondoh Y, Homma S, Muraishi K, et al. Real-World Safety, Tolerability and Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Final Report of Post-marketing Surveillance in Japan. Advances in Therapy. 2025;42(2):1075-1093. doi:10.1007/s12325-024-03079-2
BibTeX
@article{Inoue2025,
author = {Inoue, Yoshikazu and Ogura, Takashi and Azuma, Arata and Kondoh, Yasuhiro and Homma, Sakae and Muraishi, Kenya and Ikeda, Rie and Ochiai, Kaori and Sugiyama, Yukihiko and Nukiwa, Toshihiro},
title = {Real-World Safety, Tolerability and Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Final Report of Post-marketing Surveillance in Japan},
journal = {Advances in Therapy},
year = {2025},
volume = {42},
number = {2},
pages = {1075--1093},
doi = {10.1007/s12325-024-03079-2}
}
EUVIMED